Document:

Agreement dated July 15, 2002 - Forensic Alliance Limited

 CONFIDENTIAL TREATMENT 
  
 ORCHID BIOSCIENCES, INC. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED 406 CONFIDENTIAL TREATMENT PURSUANT TO RULE
406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  
 [*] CONFIDENTIAL
MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. 
  
  
 Exhibit 10.23 
  
 FORENSIC ALLIANCE LIMITED 
  
 and 
  
 ORCHID BIOSCIENCES EUROPE LIMITED 
  
 (acting through its Cellmark Diagnostics business) 

 CONTENTS 
  

					
			
	 1.
	 	 Interpretation
	  	3
			
	 2.
	 	 Appointment of sub-contractor
	  	4
			
	 3.
	 	 Services
	  	4
			
	 4.
	 	 Payment
	  	5
			
	 5.
	 	 Samples
	  	6
			
	 6.
	 	 Confidentiality
	  	7
			
	 7.
	 	 Force Majeure
	  	7
			
	 8.
	 	 Joint Advisory Group
	  	8
			
	 9.
	 	 Liability
	  	8
			
	 10.
	 	 Duration and Termination
	  	8
			
	 11.
	 	 Notices and service
	  	9
			
	 12.
	 	 Nature of Agreement
	  	9
			
	 13.
	 	 Jurisdiction
	  	10
			
	 14.
	 	 Non-Solicitation of Employees
	  	10

  

 Page 2 of 10 

 THIS AGREEMENT is made the 15th day of July 2002 between 
  

	(1)	FORENSIC ALLIANCE LIMITED, whose registered office is at 329 Harwell, Didcot Oxon OX1 1 0QJ (“FAL”); and 

  

	(2)	ORCHID BIOSCIENCES EUROPE LIMITED, whose registered office is at 22 Blacklands Way, Abingdon, Oxon OX14 1DY, acting through its Cellmark Diagnostics business of 8 Blacklands
Way, Abingdon Business Park, Abingdon, Oxon OX14 1 DY (“Cellmark”). 

  
 WHEREAS: 
  

	(A)	Cellmark is a provider of DNA services for forensic analysis; 

  

	(B)	FAL provides forensic testing services to third parties, including police forces; and 

  

	(C)	FAL wishes to sub-contract to Cellmark all forensic DNA testing services required by its customers. 

  
 IT IS HEREBY AGREED as follows. 
  

	1.	INTERPRETATION 

  
 In this Agreement, the following terms shall, unless the context otherwise requires, have the following meanings: 
  

	 	1.1	‘Affiliate’ means, with respect to a party, any legal entity directly or indirectly controlling, controlled by or under common control with that party. For purposes
of this Agreement, “control” means the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of the legal entity, or the right to receive more than fifty percent (50%) of the profits or earnings
of the legal entity, or the right to direct the policy decisions of the legal entity. 

  

	 	1.2	‘Calendar Year’ means each period of twelve (12) calendar months commencing on the Effective Date or any anniversary thereof. 

  

	 	1.3	Completion’ means submission of the result of the analysis of the Sample: 

  

	 	(a)	to the National DNA Database, or 

  

	 	(b)	to FAL by means of electronic mail, facsimile, letter, or any other form agreed between the parties, 

  
 whichever is the earlier. 
  

	 	1.4	‘Confidential Information’ means contract documents or any information contained therein or in any material provided to Cellmark by FAL pursuant to the Agreement or
prepared by Cellmark pursuant to the Agreement, all of which information will be deemed confidential. 

  

	 	1.5	‘Effective Date’ means the date first above writen 

  

	 	1.6	‘Force Majeure’ means, in relation to either party, any circumstances beyond the reasonable control of that party (including, without limitation, any strike,
lock-out or other form of industrial action). 

  

	 	1.7	‘Hit Confirmation’ means where a speculative sample results in a hit against the DNA database which would then require an evidential sample to be taken and
profiled. 

  

 Page 3 of 10 

	 	1.8	‘Police Force’ means any police force, coroner, accident investigation authority or any other similar bodiy by whom FAL is engaged to provide the Services.

  

	 	1.9	‘Sample’ means blood, mouth swab/wash, stained material or any other biological sample accepted by Cellmark for DNA analysis. 

  

	 	1.10	‘Services’ means any DNA related services, including, but not limited to, the analysis of Samples from crime scenes, and associated reference Samples, using a
variety of DNA technologies including Short-Tandem Repeats and Single Locus Probing. 

  

	2.	APPOINTMENT OF SUB CONTRACTOR 

  

	 	2.1.	FAL hereby appoints Cellmark on an exclusive basis, and Cellmark accepts such appointment, to provide the Services as a sub-contractor to FAL. During the term of this Agreement, FAL
shall not provide (and shall reqire any Affiliate not to provde) the Services itself and shall not appoint (and shall require any Affiliate not to appoint) any sub-contractor other than Cellmark to provide the Services, except under the following
circumstances: 

  

	 	(a)	with the written permission of Cellmark and/or 

  

	 	(b)	to the extent necessary to comply with legislation. 

  

	 	2.2.	During the term of this Agreement, Cellmark shall not provide (and shall require any Affiliate not to provide) the Services to the Police Forces other than as a sub-contractor to
FAL pursuant to this Agreement, except under the following circumstances: 

  

	 	(a)	with the written permission of FAL and/or 

  

	 	(b)	to the extent necessary to comply with legislation. 

  

	 	2.3.	Subject to the prior written consent of FAL (such consent not to be unreasonably withheld), Cellmark shall be entitled to sub-contract to third parties for the provision of the
Services referred to Cellmark by FAL pursuant to Clause 2.1. Cellmark shall ensure that any sub-contractor so appointed provides the Services to the standards of quality required under this Agreement. 

  

	 	2.4.	In the event that Cellmark sub-contracts the Services to a third party, Cellmark shall ensure that all of the terms and conditions herein shall be applied to the agreement between
Cellmark and the third party. 

  

	3.	SERVICES 

  

	 	3.1.	Each party shall use its reasonable endeavours to minimise the turnaround times for provision of the Services to the Police Force(s). Cellmark acknowledges that the market demands
are moving towards a [*] turnaround or less for all sample types. Subject to Clause3.2, the turnaround times for the Services shall, unless otherwise agreed between the parties, be as follows: 

  

	 	(a)	The standard turn around time for all CJA (Criminal Justice Act), Speculative and Crime Stain Samples (“Major Crime Samples”) will be [*] from receipt of the Sample by
Cellmark. Cellmark will ensure that at least [*] of the Major Crime Samples received shall be completed within the turn around time mentioned herein. 

  

 Page 4 of 10 

	 	(b)	Cellmark will use its best endeavours to achieve a [*] turnaround time on [*] of Major Crime Samples derived from case work by July 1, 2002. 

  

	 	(c)	FAL and Cellmark agree by mutual consent that turn around times may be extended in order to obtain a result for the more difficult case work samples. 

  

	 	(d)	DNA profiling in respect of Samples submitted for speculative search against the National DNA Database will be completed and the results made ready for inclusion on the National DNA
Database within [*] of submission of the Sample to Cellmark. 

  

	 	(e)	Orchid agrees to provide a CJA (Criminal Justice Act) service with turnaround times as agreed by the parties with the individual Police Force on a case by case basis.

  

	 	(f)	All CJA samples will be retained by Orchid for a minimum of [*] and thereafter subject to contractual agreement with FAL. 

  

	 	(g)	For all other samples, Orchid will: 

  

	 	(i)	return to FAL all unconsumed exhibits and items; 

  

	 	(ii)	dispose of consumed items and residues; and 

  

	 	(iii)	retain surplus DNA as extracts. 

  

	 	3.2.	Where, due to the needs of its customers (and in particular the Police Forces), FAL requires a turnaround time quicker than as specified in Clause 3.1 (e.g. a [*] turn around),
Cellmark shall ensure that the said Services are available. For the avoidance of doubt, it is estimated that each major Police Force (presently [*] in total) shall require the said Services approximately [*] times per Calendar Year. Such rapid turn
around Samples will be charged on a case by case basis at the then prevailing rate as agreed in the price list in Appendix 1 hereto (or any agreed updated version thereof). 

  

	 	3.3.	In the case of Hit Confirmations, a final written report will be supplied to FAL in respect of the Services within (3) weeks of completion of the Services, but will be extended by
mutual consent for more difficult cases. 

  

	4.	PAYMENT 

  

	 	4.1.	The rate of fees per Sample chargeable by Cellmark is listed in Appendix I. Fees for categories of Samples other than as listed above shall be as agreed by the parties on a case by
case basis. These prices will be reviewed on an annual basis in March and implemented in June of the same year. 

  

	 	4.2.	Cases requiring faster than normal turnaround as outlined in Clause 3.2 above will be charged at the rate specified in Appendix I provided that additional expenses incurred
(including overtime payments, additional subsistence, or transport costs) shall be invoiced separately and paid by FAL. Cellmark will provide an estimate of such costs to FAL prior to commencing the work. 

  

	 	4.3.	Fees for Cellmark employees as expert witnesses or as a result of their participation in necessary meetings and case conferences and any reasonable expense incurred as a consequence
of such attendance shall be agreed between Orchid and FAL, and invoiced to FAL and paid separately. 

  

 Page 5 of 10 

	 	4.4.	For additional Services in support of major crimes (e.g. specialist extractions, including LCN Samples) Cellmark will charge FAL for an agreed number of hours determined by the
nature of the crime samples and the estimated additional time involved. FAL agrees to include such additional charges on its price list and as part of its quotation procedure to Police Forces. 

  

	 	4.5.	Cellmark shall submit a written invoice to FAL on or after the end of each month for the provision of the Services in that month. On receipt of Cellmark’s written invoice, FAL
shall make payment by the end of the month following the month in which the invoice was received EXCEPT THAT FAL shall 

  

	 	(a)	pay each invoice that is issued after 1 September 2002 within the period of [*] next following the date of receipt of the relevant invoice; and 

  

	 	(b)	pay each invoice issued after 1 April 2003 within the period of [*] next following the date of receipt of the relevant invoice. 

  

	 	4.6.	When FAL is limited contractually to specific prices, the parties will negotiate suitable rates for the Services of Cellmark. In general, the principle shall be that [*]

  

	5.	SAMPLES 

  

	 	5.1.	FAL shall examine items and confirm the presence of particular types of body fluid and make its decision as to which item to submit to Cellmark for DNA analysis. Cellmark will use
its best endeavours to carry out the Services required, but reserves the right to refuse to analyse Samples which, in its opinion, are unsuitable. 

  

	 	5.2.	FAL will endeavour to submit stains in suitable format as agreed with Cellmark. 

  

	 	5.3.	In all cases, the Samples submitted to Cellmark shall be accompanied by clear written instructions for analysis and other information deemed necessary (including, where available,
details or indication of hazardous materials), together with details of the required turnaround times in writing. 

  

	 	5.4.	FAL undertakes to ensure that all documentation is in place to demonstrate continuity of items sent to Cellmark. 

  

	 	5.5.	In the event that complete items are sent to Cellmark for analysis, FAL shall obtain permission of the Police Force (or any other relevant customer of FAL) for Cellmark to cause any
damage to the item necessary to extract DNA from it. 

  

	 	5.6.	Cellmark reserves the, right to request further Samples in particular, but without limitation, in cases where the Sample delivered does not comply with instructions, or where the
quality or quantity of the Sample received is inadequate for analysis. 

  

 Page 6 of 10 

	 	5.7.	Unused Samples or parts thereof will be returned by Cellmark to FAL after completion of the final report unless otherwise instructed in writing. 

  

	 	5.8.	Subject to its confidentiality obligations set forth in Clause 6, Cellmark shall be entitled to use the data and results it produces in internal studies within Cellmark relating to
such matters as statistical and genetic parameters for DNA testing. 

  

	 	5.9.	FAL staff will interpret results submitted by Cellmark using guidelines agreed with Cellmark’s Forensic Manager. 

  

	6.	CONFIDENTIALITY 

  

	 	6.1.	Except as provided by Clause 6.2, the parties shall at all times during the continuance of this Agreement and after its termination: 

  

	 	(a)	use their best endeavours to keep all Confidential Information confidential and accordingly not to disclose any Confidential Information to any other person; and

  

	 	(b)	not use any Confidential Information for any purpose other than the performance of the obligations under this Agreement without the express prior written permission of the party
which disclosed such information. 

  

	 	6.2.	Any Confidential Information may be disclosed by either party to 

  

	 	(a)	any governmental or other authority or regulatory body; or 

  

	 	(b)	any employees of the party receiving the Confidential Information or of any of the aforementioned persons, 

  

	 	(c)	to such extent only as is necessary for the purposes contemplated by this Agreement, or as is required by law. 

  

	 	6.3.	Each party shall be relieved from its obligations under Clause 6.1 to the extent that such Confidential Information: 

  

	 	(a)	enters the public domain, otherwise than through a breach of this Agreement; or 

  

	 	(b)	can be demonstrated to have already been known by the receiving party at the time of disclosure by the other party; or 

  

	 	(c)	was lawfully acquired by the receiving Party from others who had full rights to disclose it to the receiving Party. 

  

	 	6.4.	Cellmark shall ensure that its staff and sub-contractors are aware of and observe the requirements of the Data Protection Act 1998 and of the consequences of breaches of the Data
Protection Act 1998, and that it is registered as required pursuant to the Data Protection Act 1998. 

  

	7.	FORCE MAJEURE 

  

	 	7.1.	If either party is affected by Force Majeure it shall forthwith notify the other party of the nature and extent thereof. 

  

	 	7.2.	Neither party shall be deemed to be in breach of this Agreement, or otherwise be liable to the other, by reason of any delay in performance, or non-performance, of any of its
obligations hereunder (except for payment obligations) to the extent that such delay or non-performance is due to any Force Majeure of which it has notified the other party; and the time for performance of that obligation shall be extended
accordingly. 

  

 Page 7 of 10 

	 	7.3.	The party so affected by Force Majeure shall use all reasonable endeavours to mitigate the effects of such upon the other party. 

  

	 	7.4.	If the Force Majeure in question prevails for a continuous period in excess of thirty (30) days, the parties shall enter into bona fide discussions with a view to alleviating its
effects, or to agreeing upon such alternative arrangements as may be fair and reasonable. 

  

	8.	REPRESENTATION 

  

	 	8.1.	Cellmark shall be entitled to have a representative on any advisory group relating to DNA technologies established by FAL and the Police Force unless the Police Force expressly
object to such representation. 

  

	9.	LIABILITY AND WARRANTY 

  

	 	9.1.	The liability of Cellmark for all claims relating to this Agreement or the provision of the Services (other than claims relating to death or personal injury caused by the negligence
of Cellmark) shall not exceed in aggregate the sum of [*] 

  

	 	9.2.	Cellmark shall not be liable for any claims arising from the negligence or willful misconduct of FAL. 

  

	10.	DURATION AND TERMINATION 

  

	 	10.1.	Subject as provided in Clause 10.2, below, this Agreement shall come into force on the Effective Date and shall continue in force for a period of five (5) years and thereafter
unless or until terminated by either party giving to the other not less than twelve (12) months’ written notice on the anniversary date of this Agreement. 

  

	 	10.2.	Either party shall be entitled forthwith to terminate this Agreement by written notice to the other if: 

  

	 	(a)	that other party commits any material breach of any of the provisions of this Agreement and, in the case of a breach capable of remedy, fails to remedy the same within twenty-eight
(28) days after receipt of a written notice giving full particulars of the breach and requiring it to be remedied; 

  

	 	(b)	an encumbrancer takes possession or a receiver or receiver manager is appointed over any of the property or assets of that other party; 

  

	 	(c)	that other party makes any voluntary arrangement with its creditors or becomes subject to an administration order; 

  

	 	(d)	that other party goes into liquidation (except for the purposes of amalgamation or reconstruction and in such manner that the company resulting therefrom effectively agrees to be
bound by or assume the obligations imposed on that other party under this Agreement); 

  

	 	(e)	anything analogous to any of the foregoing under the law of any jurisdiction occurs in relation to that other party; or 

  

	 	(f)	that other party ceases, or threatens to cease, to carry on business. 

  

 Page 8 of 10 

	 	10.3.	For the purposes of Clause 10.2(a), a breach shall be considered capable of remedy if the party in breach can comply with the provision in question in all respects other than as to
the time of performance (provided that time of performance is not of the essence). 

  

	 	10.4.	Any waiver by either party of a breach of any provision of this Agreement shall not be considered as a waiver of any subsequent breach of the same or any other provision thereof.

  

	 	10.5.	The rights to terminate this Agreement given by Clause 10.2 shall be without prejudice to any other right or remedy of either party in respect of the breach concerned (if any) or
any other breach. 

  

	 	10.6.	Orchid and FAL will develop a joint five (5) year expanded business plan to include DNA sales projections. FAL will take the lead in all sales and marketing initiatives. The five
(5) year business plan will include new targeted DNA sales initiatives to maximise business. Such sales initiatives will involve direct participation of individuals from both parties as required. 

  

	11.	NOTICES AND SERVICE 

  

	 	11.1.	Any notice or other information required or authorised by this Agreement to be given by either party to the other or any legal proceedings arising out of this Agreement shall be
deemed to have been given or served when a legible copy of the same has been received by the other party at: 

  

			
	 Forensic Alliance Limited
	 	 Orchid BioSciences Europe Limited

	 F5 Culham Science Centre
	 	 8 Blacklands Way

	 Abingdon
	 	 Abingdon Business Park

	 Oxfordshire OX14 3ED
	 	 Abingdon

	 England
	 	 Oxon OX14 l DY

	 Attention: Graham Wren
	 	 England

	 	 	 Attention: Chris Ashton

  

	12.	NATURE OF AGREEMENT 

  

	 	12.1	Neither party may assign this Agreement and the rights and obligations hereunder without the written consent of the other (such consent not to be unreasonably withheld or delayed),

  

	 	12.2	Nothing in this Agreement shall create, or be deemed to create, a partnership or the relationship of principal and agent or employer and employee between the parties.

  

	 	12.3	This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and each party acknowledges that, in entering into this Agreement, it does
not do so on the basis of, and does not rely on, any representation, warranty or other provision except as expressly provided herein, and all conditions, warranties or other terms implied by statute or common law are hereby excluded to the fullest
extent permitted by law. 

  

	 	12.4	No amendment to this Agreement should be effective unless made in writing by an authorised signatory of each party. 

  

 Page 9 of 10 

	13.	JURISDICTION 

  

	 	13.1.	This Agreement shall be governed by the Laws of England, and each party hereby submits to the exclusive jurisdiction of the English Courts. 

  

	14.	NON-SOLICITATION OF EMPLOYEES 

  
 It is agreed that neither party shall directly solicit or seek to employ the other party’s employees without the prior written consent of that party. 
  
 IN WITNESS whereof the authorised representatives of the parties have executed this Agreement
on the date stated above: 
  
 Signed for and on behalf of FORENSIC ALLIANCE
LIMITED by 
  

			
	 (Signature)
	 	  

	 (Name)
	 	  

	 (Position)
	 	  

  
 Signed for and on behalf of ORCHID
BIOSCIENCES EUROPE LIMITED by 
  

			
	 (Signature)
	 	  

	 (Name)
	 	  

	 (Position)
	 	  

  

 Page 10 of 10Employment Agreement - Paul J. Kelly

 Exhibit 10.24 
  
 FIRST AMENDMENT 
 TO 
 EMPLOYMENT AGREEMENT 
  
 THIS FIRST AMENDMENT to that certain Employment Agreement, dated May 16, 2003, (the “Employment Agreement”) between Orchid BioSciences, Inc., a
Delaware corporation (the “Company”), and Paul James Kelly (the “Employee”) is made effective as of November 3, 2003 (the “Effective Date”). 
  
 WHEREAS, Section 7 of the Employment Agreement provides that the Employment Agreement may be modified with the signed
written consent of both the Company and the Employee; and 
  
 WHEREAS, the Company has determined that it is in the best interests of the Company and its stockholders that the Employment Agreement be amended as provided herein; 
  
 WHEREAS, the Employee has agreed to the amendments to the Employment Agreement as set forth herein; 
  
 NOW, THEREFORE, the Employment Agreement is hereby amended as follows:

  
 1. Clause (ii) of Section 3(g) of the Employment Agreement is
amended in its entirety to read as follows: 
  

	 	(ii)	Merger/Sale of Assets. A merger or consolidation of the Company, whether or not approved by the Board of Directors, other than a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such entity) at least 50% of the
total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation outstanding immediately after such merger or consolidation, or the consummation of an agreement for the sale or disposition
by the Company of all or substantially all of the Company’s assets. “Substantially all of the Company’s assets” shall be deemed to include the assets of all business units and/or divisions of the Company and all of its
affiliates. 

 2. The second sentence of Section 4(a) of the Employment Agreement is amended in its entirety to read as
follows: 
  
 If employment is terminated under the provisions of
Section 3(e) or 3(g), the term “Severance Pay Period” shall mean the period commencing on the effective date of the Employee’s letter giving notice of his resignation and ending twenty-four (24) months subsequent to the date of such
resignation letter. 
  
 3. The final sentence of Section 4(a) of
the Employment Agreement is deleted in its entirety. 
  
 4.
Section 5 of the Employment Agreement is amended to insert the following as a new Section 5(k): 
  
 (k) The Employee shall be entitled to a lump-sum cash payment equal to 100% of his then-current annualized rate of base pay upon the earliest of the
following to occur while the Employee is employed under this Agreement: 
  

	 	(i)	a Change in Control (as defined in Section 3(g) of this Agreement); 

  

	 	(ii)	the consummation of the sale or other disposition of all or substantially all of the Company’s assets as defined in the amendment to Section 3(g)(ii) set forth above; or

  
 Except as herein modified, the Employment
Agreement shall remain in full force and effect. 
  

 2 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to the Employment Agreement on the
dates provided below, effective as of the Effective Date. 
  

			
	 ORCHID BIOSCIENCES, INC.

		
	 By:
	 	     /s/ George Poste

	 [name of chairman]

	 Title:
	 	 [Chairman, Board of Directors]

	 Date:
	 	 October [    ], 2003

	
	 PAUL JAMES KELLY

	
	     /s/

	 Date:
	 	 October [    ], 2003

  

 3 

  
 Orchid BioSciences INC.

  
 EMPLOYMENT AGREEMENT 
  
 This Agreement is entered into between Orchid BioSciences, Inc. a Delaware corporation (the
“Company”) and Paul James Kelly (the “Employee”) on May 16, 2003. In consideration of, and as a condition of Employee’s employment by Company and of the compensation to be paid to Employee by Company, and in recognition of
the fact that Employee will have access to the Company’s confidential, proprietary, and trade secret information, Company and Employee agrees to the terms and conditions set forth in this agreement as follows: 
  
 1. Position The Company and the Employee agree that Employee will serve as
Chief Executive Officer of the Company and will serve on the Board of Directors of the Company. Employee agrees that Employee’s employment with the Company is on an at will basis, is for no specified term and may be terminated by the Company at
any time, with or without Cause (as defined in Section 3 herein). Similarly, Employee may terminate employment with the Company at any time, for any reason upon written notice as provided in Section 3 of this agreement. Employee understands and
agrees that the at will nature of Employee’s employment relationship with Company cannot be changed or modified, except by a written agreement signed by the Chairman of the Board of Directors of Company and the Employee. The Employee’s
performance will be reviewed formally on an annual basis in conjunction with an annual salary period. 
  
 2. Start Date; Nature of Relationship. Employee’s employment with the Company will begin on June 2, 2003. The Employee will perform for the Company such duties that are customarily assigned to such
position and as may be designated by the Company from time to time. The Employee will be expected to devote all of his working time to the performance of his duties with the Company; provided the Employee may continue to serve as a director of
AgaMatrix, Inc. and MedCenter Solutions, Inc. spending no more than ten (10) total business days per year on such activities. 
  
 3. Termination  
  
 Employee’s employment hereunder shall terminate upon the occurrence of any of the following events: 
  
 (a) The death of Employee. 
  
 (b) Written notice of termination from the Company to Employee as a result of Employee’s incapacity or inability to further perform services as contemplated herein for 90 consecutive days or more within any
six-month period, because Employee’s physical or mental health has become so impaired as to make it impossible or impractical for Employee to perform the duties and responsibilities contemplated hereunder (Determination of the Employee’s
physical or mental health will be determined by a medical expert appointed by mutual agreement between the Company and the Employee). 

 (c) Written termination notice from the Company to Employee of Employee’s employment termination by the Company for
Cause (as hereafter defined). “Cause” shall mean that either the employee has (1) intentionally committed an act or omission that materially harms the Company; (2) continuously been grossly negligent in performance of his or her duty to
the Company, which is incapable of cure or not cured within ten (10) business days of the date of receipt by employee of its existence; (3) committed an act of moral turpitude; (4) committed an act of fraud or material dishonesty in discharging his
duties to the Company; (5) a material breach of this agreement or any other agreement with the Company or (6) any other act or commission that may be deemed grounds for a “cause” termination under Delaware state law. 
  
 (d) 6 months notice from the Company to Employee that Employee’s employment is being
terminated without Cause; 
  
 (e) Employee’s written notice of resignation to
the Company due to a Constructive Dismissal (as hereafter defined). A “Constructive Dismissal” shall mean the occurrence, without Employee’s express written consent, of any of the following provided, however, there shall be no
Constructive Dismissal unless the employee provides the Board of Directors with written notice reasonably detailing the purported basis for Constructive Dismissal and if the Company fails to remedy within 10 days thereafter: 
  

	 	(i)	The assignment of duties or responsibilities to Employee materially inconsistent with the position held by Employee as of the Effective Date or a substantial diminution in the
nature or status of Employee’s position, authority, duties or responsibilities; or 

  

	 	(ii)	A material breach by the Company of any term or condition of this Agreement; 

  

(f) Employee’s written notice of resignation to the Company for any reasons other than due to a Constructive Dismissal or Change of Control. 
  
 (g) Employee’s written notice of resignation to the Company following Change of Control.
For the purposes of this agreement, Change of Control is; 
  

	 	(i)	Ownership. Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “Beneficial Owner” (as
defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose the
Company or its Affiliates or any employee benefit plan of the Company). 

  

	 	(ii)	Merger/Sale of Assets. A merger or consolidation of the Company whether or not approved by the Board of Directors, other than a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of
the total voting power represented by the voting securities of the Company or such 

  

 2 

	 	    	surviving entity or parent of such corporation outstanding immediately after such merger or consolidation, or the stockholders of the Company approve an agreement for the sale or
disposition by the Company of all or substantially all of the Company’s assets. 

  
 4. Payment After Termination. 
  
 (a) Following termination of Employee’s employment, all payments and benefits provided to Employee under this Agreement shall cease as of the date of such termination, except that in the event Employee’s employment is terminated
(i) by the Company pursuant to Section 3 (d) and the Company elects to make payment to Employee in lieu of providing Employee with six (6) months notice of such termination or (ii) by Employee pursuant to Section 3 (e) or (g), then for the
“Severance Pay Period” (as hereafter defined) (1) the Company shall pay Employee severance pay in the form of continuation of Employee’s base salary, less standard deductions and withholdings, such payments to be made at the same time
as Employee’s salary otherwise would have been payable, and (2) if Employee elects continued coverage under COBRA, the Company will reimburse Employee for the same portion of Employee’s health insurance premiums for Employee and
Employee’s family, to the same extent the Company paid those premiums during Employee’s employment. If employment is terminated under the provision of Section 3 (g) the term “Severance Pay Period” shall mean the period commencing
on the effective date of the letter notice of resignation of the Employee and ending on twenty four (24) months subsequent to the date of the resignation letter. If employment is terminated under the provisions of 3 (e) the following Severance Pay
Period will apply; 
  
 (i) Six (6) months if termination is
prior to the first anniversary of Start Date,  
  
 (ii)
Twelve (12) months if termination is on or after the first anniversary of Start Date but prior to the third anniversary of the Start Date, or 
  
 (iii) Eighteen (18) months if termination is on or after the third anniversary of the Start Date,  
  
 (b) The employee may elect, subject to agreement by the company, to have all or part of the
salary payable under the Severance Pay Period in 4(a) as a lump sum, less standard deductions and withholdings. 
  
 5. Compensation, Equity and Benefits 
  
 (a) The Employee’s initial base pay shall be at an annualized rate of $350,000 per year, minus customary deductions for federal and state taxes and the like.
The Board will review the Employee’s base pay rate on an annual basis, during the first calendar quarter for each year, with any increase becoming effective as of April 1. The Employee, will also be eligible to receive an Annual Performance
Bonus for each calendar year the Employee is employed by the Company (through December 31). The award and amount of any Annual Performance Bonus shall be determined by the Board based on the Employee’s performance and the overall performance of
the Company, measured against goals that are mutually agreed upon in advance between the Employee and the Company. The bonus target for each year will be at least forty percent (40%) of the Employee’s annualized base pay rate, and the amount of
any Annual Bonus for 2003 shall be pro-rated based on the portion of 2003 during which the Company employs the Employee. 
  

 3 

 (b) The Company will grant to the Employee incentive stock options to purchase shares of the Company at an exercise price
equal to stock price at the close of trading on the day of this agreement pursuant to the terms of a formal stock option agreement(s) and the Orchid 2000 Stock Plan (except as amended by this agreement). 50,000 of such options will vest on [start
date], and the remaining 150,000 to vest monthly thereafter in 48 equal tranches of 3,125 over the next four (4) years. 
  
 (c) Employee shall be entitled to participate in all employee benefit, welfare and other plans, practices, policies and programs and fringe benefits of the Company on a
basis no less favorable than those provided to other similarly situated executives of the Company. Employee understands that, except when prohibited by applicable law, the Company’s employee benefit plans and fringe benefits may be amended,
enlarged, diminished or terminated by the Company from time to time, in its sole discretion. 
  
 (d) Upon submission of itemized expense statements in the manner specified by Company, the Company will pay Employee’s reasonable travel and other reasonable business expenses incurred by Employee in the
furtherance of and in connection with Employee’s employment hereunder. 
  
 (e) The Company, at its expense, will purchase life insurance on the Employee’s life in the face amount of not less than three (3) times your base pay rate with a beneficiary designated by the Employee and the Employee shall receive
deferred compensation through contributions of five percent (5%) of Employee’s annual base pay per year in accordance with the terms of the Orchid Biocomputer, Inc. Executive Deferred Compensation Plan.  
  
 (f) Employee will be entitled to twenty-five (25) vacation days and five (5) sick days per
year that Employee remains employed by the Company, subject to the terms of normal Company vacation and sick leave policies. 
  
 (h) The Company agrees to reimburse OmniViz Incorporated up to $50,000 that Employee may be obligated to repay to OmniViz Inc., upon presentation of a reasonably detailed
written demand for repayment from such employer. 
  
 (i) Should the Company
terminate the Employee’s employment within twelve (12) months of the Start Date under the provisions of Section 3 (c), and then the Employee will be required to refund to The Company the full amount (100%) of reimbursement/relocation monies
within ninety (90) days of the Employee’s termination. Should the Company terminate the Employee’s employment under the provisions of 3 (c) after twelve (12) months but prior to twenty-four (24) months, the Employee will be required to pay
back fifty percent (50%) of all such monies reimbursed to the employee or paid by the Company, also within ninety (90) days of termination of the Employee. 
  
 (j) If, within the twelve (12) month period following the date of this agreement, the Employee chooses to relocate his primary residence to within 50 miles of the
Company’s Head Office, the Company agrees to reimburse the Employee up to $20,000 for expenses relating to this relocation upon presentation of reasonably detailed invoices for bona fide moving expenses. 
  

 4 

 5. Representations and Warranties 
  
 (i) The Company represents and warrants that the financial projections and business plan provided to the Employee are accurate and fairly
represent the prospects of the Company and that the Company believes the recent $16 million preferred convertible financing of the Company and access to its $10,000,000 line of credit is sufficient for the Company to achieve cash flow break even in
the fourth fiscal quarter of 2003 without the need for additional financing. 
  
 (ii) Employee warrants that he is eligible to work in the United States. On the Start Date, the Employee will complete an I-9 Form and provide the Company with any of the accepted forms of identification specified on the I-9 Form.

  
 6. Confidentiality, Inventions and Non-Competition The Company
considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. Given the confidential nature of various aspects of the Company’s business, the Employee may not discuss the fact or terms
of this Offer or any employment discussions with anyone other than members of the Board (and its designees), members of Employee’s immediate family and, if relevant, the Employee’s financial advisor or lawyer. In addition, the Employee
agrees to sign and return the attached Employee Intellectual Property, Confidentiality and Non-Compete Agreement by no later than the Start Date as a condition of this offer of employment. 
  
 7. Miscellaneous This Agreement represents the Company’s and
Employee’s entire understanding with respect to the subject matter contained in this Agreement and supersedes all previous understandings, written or oral between the Company and Employee concerning the subject matters of this Agreement,
including but not limited to the Prior Agreement. This Agreement may be amended or modified only with the signed written consent of both the Company and Employee unless otherwise expressly provided. No oral waiver, amendment or modification shall be
effective under any circumstances whatsoever. 
  
 8.
Indemnification. To the fullest extent permitted by law and the Company’s certificate of incorporation and by-laws, the Company shall promptly indemnify Employee for all amounts (including, without limitation, judgments, fines,
settlement payments, losses, damages, costs and expenses (including reasonable attorneys’ fees) incurred or paid by Employee in connection with any action, proceeding, suit or investigation arising out of or relating to the performance by
Employee of services for the Company, including as a director, officer or employee of the Company. The Company also agrees to maintain a director’s and officers’ liability insurance policy covering Employee to the extent the Company
provides such coverage for its other directors and executive officers. 
  
 9.
Governing Law. This Agreement shall be governed by the law of the State of Delaware. The Company shall pay to Employee all legal fees and expenses incurred by Employee in disputing in good faith any issue hereunder relating to the
termination of Employee’s employment or in seeking in good faith to obtain or enforce any benefit or right provided by this Agreement. 
  

 5 

 10. Severability. Should any provisions of this Agreement be held by a court of law to be illegal, invalid
or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby. 
  
 11. Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated:
(1) by personal delivery when delivered personally; (2) by overnight courier upon written verification of receipt; (3) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (4) by certified or registered
mail, return receipt requested, upon verification of receipt. Notices to Employee shall be sent to the last known address in the Company’s records or such other address as Employee may specify in writing. Notices to the Company shall be sent to
the Company’s Chairman or to such other Company representative as the Company may specify in writing. 
  
 BY PLACING MY SIGNATURE HEREUNDER, I ACKNOWLEDGE THAT I HAVE READ ALL THE PROVISIONS OF THIS AGREEMENT AND THAT I AGREE TO ALL OF ITS TERMS. 
  

					
	 EMPLOYEE:
	 	 
		
	 Date: May 16, 2003
	 	 
	 	 	     /s/

	 	 	 Employee’s Signature

	 	 	 Address:
	 	  

	 The Company
	 	 	 	  

			
	 Date: May 16, 2003
	 	 	 	 
	 	 	 By:
	 	     /s/ George Poste

			
	 	 	 Title:
	 	 Chairman, Board of Directors

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]